Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
ACN Newswire能提供全方位的服務。對於希望向媒體、業界和金融市場披露和傳播資訊的公司和組織,我們能為您安排即時的新聞發佈。ACN Newswire的新聞稿包括英文、簡體中文、繁體中文、韓文和日文等多種語言版本。
Wednesday, 24 May 2023, 15:00 HKT/SGT
Share:

來源 Access Accelerated
New Access Accelerated Global Collective Report Charts Path Forward in Fight Against Noncommunicable Diseases
Access Accelerated and Partners Unveil Findings From Six-Year Report

在瑞士日內瓦, 2023年5月24日 - (亞太商訊)  - Access Accelerated, a pioneering collective of leading biopharmaceutical and life science companies dedicated to confronting the growing global noncommunicable disease (NCD) crisis, announced the release of a six-year report: Key Lessons in Advancing Access to NCD Care: Collaboration, Connectivity, Community.

This milestone report highlights the initiative's outcomes, impact, and collective learnings between 2017 and 2022 and serves as a retrospective, a showcase for the initiative's success stories and challenges, and a much-needed vision for the future.

Michael Fredrich, Lead Access to Medicine Non-Communicable Diseases at Bayer Pharmaceuticals and Chair of the Access Accelerated Board, commented, "With the 2030 deadline for the UN Sustainable Development Goals approaching fast, which include Universal Health Coverage, it's more important than ever that we make the most out of our resources and approach this fight strategically. This report gives us the opportunity to critically evaluate our past and use key learnings for the future. It is essential that we share insights and learn from our collective efforts. Much work lies ahead, but this report serves as a valuable foundation for effectively addressing NCDs."

This initiative's impact has already been felt widely. Access Accelerated and its strategic partners - the City Cancer Challenge Foundation, NCD Alliance, PATH, the World Bank and the World Heart Federation - have helped improve access to NCD screening, diagnosis, and treatment around the world, reaching over 700 million people through 54 partner projects in 37 countries and catalyzing $US1.6 billion in investment in 2022 alone. By the end of phase 2 (2020-2022), this number totalled $US3.7 billion. In the same period, Access Accelerated partner projects contributed to policy change in 35 countries and 13 projects were scaled to national level, moving away from pilot phase to locally embedded projects.

Six years since its founding, the initiative has accumulated a wealth of hard-won knowledge and experience. The report highlights those learnings, including the crucial role of open, transparent communication in measuring intangible impact of partnerships, the ways flexible long-term funding can open the way for locally embedded solutions, and why community- and patient-centric approaches are essential to sustainability. By capturing impacts beyond hard numbers, the report demonstrates the importance of local engagement, trust, and social capital in improving NCD outcomes over time.

According to Dr. Juan Pablo Uribe, World Bank's Global Director for Health, Nutrition & Population and Director of the Global Financing Facility, the report demonstrates the importance of rigorous monitoring and reporting. "Learning from our successes and challenges is absolutely necessary if we are going to shape more efficient and effective initiatives that can respond to the growing NCD burden on countries around the world. That's why we're excited to have the insights offered by this report to inform future initiatives and are grateful to the partnership with Access Accelerated which has led to meaningful action in creating sustainable change."

Visit www.accessaccelerated.org to download the report.

About Access Accelerated

Founded in 2017, Access Accelerated is an unprecedented industry-led collective of life science companies united by the belief that no person should die from a preventable and treatable disease. Through the power of collaboration and a proven framework for cooperation, Access Accelerated brings together stakeholders across the private, public and social sectors, including implementers, decision-makers and financiers, in a shared mission of advancing action against the escalating challenge of NCDs in low- and middle-income countries and underserved communities.

Contact Information
Thuy Khuc-Bilon
Communications Manager
info@accessaccelerated.org
+41 79 473 0341

話題 Press release summary

部門 制药及生物技术, 健康与医药
http://www.acnnewswire.com
From the Asia Corporate News Network

Copyright © 2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network


Latest Press Releases
Autonomous Driving Enters the Core Value Realization Phase: What Anchors CIDI's Valuation?  
Dec 29, 2025, 17:20 HKT/SGT
USAS Building System Advances Toward Hong Kong Listing: A Top-Three Industrial Prefabricated Steel Structure Solution Provider, with an Emerging Overseas Growth Curve  
Dec 29, 2025, 14:48 HKT/SGT
Taxinexo Advances Large-Scale Commercial Deployment of Level 4 Autonomous Vehicles Across the United States  
Dec 26, 2025, 22:00 HKT/SGT
Honda Newly Launches "Discover Honda" Content Curation Media Platform  
Friday, December 26, 2025 4:34:00 PM
Mazda Selected for A List in CDP Water Security for the First Time  
Friday, December 26, 2025 4:19:00 PM
Fujitsu Develops Fujitsu Kozuchi Physical AI 1.0 for Seamless Integration of Physical and Agentic AI  
Friday, December 26, 2025 1:04:00 PM
Establishment of DOCOMO Innovation Fund IV, a Corporate Venture Investment Fund  
Friday, December 26, 2025 12:53:00 PM
The General Incorporated Association Generative AI Japan Announces the Winners of the Japan Generative AI Award 2025  
Friday, December 26, 2025 10:00:00 AM
BCQ (01963.HK) to Pay RMB 585 Million Cash Dividend, Driving Share Price and Yield Upside  
Thursday, December 25, 2025 5:23:00 PM
Avantor Appoints Gladys Wang as Vice President, Bioprocessing Commercial, Asia, Middle East & Africa  
Dec 24, 2025, 12:20 HKT/SGT
More Press release >>
Copyright © 2025 ACN Newswire - Asia Corporate News Network
頂部 | 關於我們 | 服務 | 合作夥伴 | 聯繫 | 隱私權政策 | 使用條款 | RSS
美國: +1 214 890 4418 | 中國: +86 181 2376 3721 | 香港: +852 8192 4922 | 新加坡: +65 6549 7068 | 東京: +81 3 6859 8575